Published Online
on July 5, 2005

A more recent version of this article appeared on July 12, 2005

This Article Full Text (PDF) All Versions of this Article: 112/2/171    most recent CIRCULATIONAHA.104.517565v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tonelli, M. Articles by Curhan, G. C. Search for Related Content PubMed PubMed Citation Articles by Tonelli, M. Articles by Curhan, G. C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Kidney Diseases Kidney Failure Related Collections Other Treatment Lipid and lipoprotein metabolism Related Article

Submitted on October 28, 2004
Revised on March 3, 2005
Accepted on March 16, 2005

Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease

Marcello Tonelli MD, SM^*, Chris Isles MD, Timothy Craven MSPH, Andrew Tonkin MD, Marc A. Pfeffer MD, PhD, James Shepherd MD, Frank M. Sacks MD, Curt Furberg MD, Stuart M. Cobbe MD, John Simes MD, MSc, Malcolm West MD, Chris Packard MD, and Gary C. Curhan MD, ScD

From the Division of Nephrology and Division of Critical Care Medicine, University of Alberta, and Institute of Health Economics, Edmonton, Alberta, Canada (M.T.); Department of Medicine, Dumfries and Galloway Royal Infirmary, Dumfries, Scotland, UK (C.I.); Wake Forest University School of Medicine, Winston-Salem, NC (T.C., C.F.); Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia (A.T.); Cardiovascular Division, Brigham and Women’s Hospital, Boston, Mass (M.A.P.); University of Glasgow, Glasgow, Scotland, UK (J.S., S.M.C.); Department of Nutrition, Harvard School of Public Health, Boston, Mass (F.M.S.); University of Sydney, Sydney, Australia (J.S.); Department of Medicine, University of Queensland, Brisbane, Australia (M.W.); Department of Pathological Biochemistry, Glasgow Royal Infirmary, Glasgow, Scotland, UK (C.P.); and Department of Epidemiology, Harvard School of Public Health, and Renal Division and Channing Laboratory, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass (G.C.C.).

^* To whom correspondence should be addressed. E-mail: mtonelli{at}ualberta.ca.

Background--Limited data suggest that HMG-CoA reductase inhibitors (statins) reduce rates of kidney function loss. We performed this analysis to determine whether pravastatin reduced the rate of kidney function loss over 5 years in people with or at high risk for coronary disease.

Methods and Results--This was a post hoc subgroup analysis of data from 3 randomized double-blind controlled trials comparing pravastatin 40 mg/d and placebo in subjects with a previous acute coronary syndrome or who were at high cardiovascular risk. The primary outcome was the rate of change in estimated glomerular filtration rate (GFR; in mL/min per 1.73 m²/y). The Modified Diet and Renal Disease Study (MDRD) and Cockcroft-Gault equations were used to estimate GFR. We studied 18 569 participants, 3402 (18.3%) of whom had moderate chronic kidney disease as defined by an estimated GFR of 30 to 59.9 mL/min per 1.73 m² body surface area. In subjects with moderate chronic kidney disease at baseline, pravastatin reduced the adjusted rate of kidney function loss by 34%, although the absolute reduction in the rate of loss was small (0.22 mL/min per 1.73 m²/y by MDRD-GFR; 95% CI, 0.07 to 0.37). Pravastatin did not reduce the frequency of 25% decreases in kidney function in this group when MDRD-GFR was used to estimate GFR (relative risk [RR], 0.84; 95% CI, 0.66 to 1.06). When all 18 569 subjects were considered, pravastatin reduced the adjusted rate of kidney function loss by 8% (0.08 mL/min per 1.73 m²/y by MDRD-GFR; 95% CI, 0.01 to 0.15) and the risk of acute renal failure (RR, 0.60; 95% CI, 0.41 to 0.86) but did not significantly reduce the frequency of a 25% decline in kidney function by MDRD-GFR (RR, 0.94; 95% CI, 0.88 to 1.01).

Conclusions--Pravastatin modestly reduced the rate of kidney function loss in people with or at risk for cardiovascular disease. However, the primary indication for the use of statins in people with or at risk for coronary events remains the reduction in mortality that results from their use.

Key words: cholesterol • statins • kidney

Related Article:

Issue Highlights
Circulation 2005 112: 147. [Extract] [Full Text]

This article has been cited by other articles:

				M. A. Pfeffer, E. A. Burdmann, C.-Y. Chen, M. E. Cooper, D. de Zeeuw, K.-U. Eckardt, J. M. Feyzi, P. Ivanovich, R. Kewalramani, A. S. Levey, et al. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease N. Engl. J. Med., November 19, 2009; 361(21): 2019 - 2032. [Abstract] [Full Text] [PDF]

				Y. Zuo, P. Yancey, I. Castro, W. Khan, M. Motojima, I. Ichikawa, A. B. Fogo, M. F. Linton, S. Fazio, and V. Kon Renal Dysfunction Potentiates Foam Cell Formation by Repressing ABCA1 Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1277 - 1282. [Abstract] [Full Text] [PDF]

				C. M. O'Seaghdha, V. Perkovic, T. H. Lam, S. McGinn, F. Barzi, D. F. Gu, A. Cass, I. Suh, P. Muntner, G. G. Giles, et al. Blood Pressure Is a Major Risk Factor for Renal Death: An Analysis of 560 352 Participants From the Asia-Pacific Region Hypertension, September 1, 2009; 54(3): 509 - 515. [Abstract] [Full Text] [PDF]

				K. L. Adeney, D. S. Siscovick, J. H. Ix, S. L. Seliger, M. G. Shlipak, N. S. Jenny, and B. R. Kestenbaum Association of Serum Phosphate with Vascular and Valvular Calcification in Moderate CKD J. Am. Soc. Nephrol., February 1, 2009; 20(2): 381 - 387. [Full Text] [PDF]

				C. A. Herzog Kidney disease in cardiology Nephrol. Dial. Transplant., January 1, 2009; 24(1): 34 - 37. [Full Text] [PDF]

				C. F. Harper and T. A. Jacobson Reply J. Am. Coll. Cardiol., November 11, 2008; 52(20): 1680 - 1680. [Full Text] [PDF]

				J.-C. Fruchart, F. M Sacks, M. P Hermans, G. Assmann, W V. Brown, R. Ceska, M J. Chapman, P. M Dodson, P. Fioretto, H. N Ginsberg, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients Diabetes and Vascular Disease Research, November 1, 2008; 5(4): 319 - 335. [Abstract] [PDF]

				C. R. Harper and T. A. Jacobson Managing dyslipidemia in chronic kidney disease. J. Am. Coll. Cardiol., June 24, 2008; 51(25): 2375 - 2384. [Abstract] [Full Text] [PDF]

				E. Ritz and C. Wanner Lipid Abnormalities and Cardiovascular Risk in Renal Disease J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1065 - 1070. [Abstract] [Full Text] [PDF]

				I. H. de Boer, B. C. Astor, H. Kramer, W. Palmas, S. L. Seliger, M. G. Shlipak, D. S. Siscovick, M. Y. Tsai, and B. Kestenbaum Lipoprotein Abnormalities Associated with Mild Impairment of Kidney Function in the Multi-Ethnic Study of Atherosclerosis Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 125 - 132. [Abstract] [Full Text] [PDF]

				J. Shepherd, J. J.P. Kastelein, V. Bittner, P. Deedwania, A. Breazna, S. Dobson, D. J. Wilson, A. Zuckerman, N. K. Wenger, and for the Treating to New Targets Investigators Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease: The Treating to New Targets (TNT) Study Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1131 - 1139. [Abstract] [Full Text] [PDF]

				L. Romayne Kurukulasuriya, G. Athappan, G. Saab, A. Whaley Connell, and J. R. Sowers Review: HMG CoA reductase inhibitors and renoprotection: the weight of the evidence Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 49 - 59. [Abstract] [PDF]

				W. W. M. Saweirs and J. Goddard What are the best treatments for early chronic kidney disease?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_9): ix31 - ix38. [Full Text] [PDF]

				M.W. Merx and C. Weber Sepsis and the Heart Circulation, August 14, 2007; 116(7): 793 - 802. [Abstract] [Full Text] [PDF]

				R. C. Ozsoy, W. A. van der Steeg, J. J. P. Kastelein, L. Arisz, and M. G. Koopman Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1578 - 1586. [Abstract] [Full Text] [PDF]

				M. R. Weir Microalbuminuria and Cardiovascular Disease Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 581 - 590. [Abstract] [Full Text] [PDF]

				A. Gianella, E. Nobili, M. Abbate, C. Zoja, P. Gelosa, L. Mussoni, S. Bellosta, M. Canavesi, D. Rottoli, U. Guerrini, et al. Rosuvastatin Treatment Prevents Progressive Kidney Inflammation and Fibrosis in Stroke-Prone Rats Am. J. Pathol., April 1, 2007; 170(4): 1165 - 1177. [Abstract] [Full Text] [PDF]

				J. Atthobari, A. H. Brantsma, R. T. Gansevoort, S. T. Visser, F. W. Asselbergs, W. H. van Gilst, P. E. de Jong, L. T. W. de Jong-van den Berg, and on behalf of PREVEND study group The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3106 - 3114. [Abstract] [Full Text] [PDF]

				N. I. Parikh, S.-J. Hwang, M. G. Larson, J. B. Meigs, D. Levy, and C. S. Fox Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med, September 25, 2006; 166(17): 1884 - 1891. [Abstract] [Full Text] [PDF]

				M. E. Molitch Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1090 - 1099. [Abstract] [Full Text] [PDF]

				S. Sandhu, N. Wiebe, L. F. Fried, and M. Tonelli Statins for Improving Renal Outcomes: A Meta-Analysis J. Am. Soc. Nephrol., July 1, 2006; 17(7): 2006 - 2016. [Abstract] [Full Text] [PDF]

				J. Segura, J. A. Garcia-Donaire, M. Praga, and L. M. Ruilope Chronic Kidney Disease as a Situation of High Added Risk in Hypertensive Patients J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S136 - S140. [Abstract] [Full Text] [PDF]

				A. Rashidi, M. Rahman, M. Tonelli, C. Isles, T. Craven, C. Furberg, A. Tonkin, M. A. Pfeffer, J. Shepherd, S. M. Cobbe, et al. Letter Regarding Article by Tonelli et al, "Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease" * Response Circulation, January 31, 2006; 113(4): e59 - e60. [Full Text] [PDF]

				Statins for Kidney Disease? Journal Watch (General), August 23, 2005; 2005(823): 3 - 3. [Full Text]